Post-marketing Surveillance of Spesolimab I.V. Infusion in Improvement of Generalized Pustular Psoriasis (GPP) With Acute Symptoms in Japan
Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• GPP patients with acute symptoms who are administered Spesolimab Intravenous (I.V.) Infusion in Japan
• Patients who have never been treated with Spesolimab I.V. Infusion before enrolment
Locations
Other Locations
Japan
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo
Time Frame
Start Date: 2023-04-18
Completion Date: 2025-10-06
Participants
Target number of participants: 52
Treatments
Patients with generalized pustular psoriasis (GPP)
Related Therapeutic Areas
Sponsors
Leads: Boehringer Ingelheim